Allan Edward Rettie

University Of Washington

$24,434,501

Attributed

$25,552,784

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.6M · FY2005–20

$5M$3.8M$2.5M$1.3M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

Funding mix

By agency

NIH$41,449,044 · 13

By mechanism

P01$23,625,694 · 6

T32$7,549,539 · 1

R01$7,418,839 · 4

R24$2,236,566 · 1

P30$618,406 · 1

Top collaborators

Douglas M Fowler3 shared

Most similar at University Of Washington

Same institution · by research overlap

Rene H Levy$15,456

Others in their field

Top investigators on “In Vitro”

David Heimbrook · Leidos Biomedical Research, Inc.$553,787,942
Leonard Freedman · Leidos Biomedical Research, Inc.$310,441,779
Mark S Klempner · Tufts Medical Center$128,021,180
Florian Krammer · Icahn School Of Medicine At Mount Sinai$104,723,856
Lynn Briscoe · Leidos Biomedical Research, Inc.$94,686,873
Dennis R. Burton · Scripps Research Institute$79,204,175

Research focus

In VitroBaseCytochrome P450GenesIn VivoPharmaceutical PreparationsInhibitor/AntagonistEnzymesMetabolismDrug InteractionsVariantWarfarinGeneticCyp2c9 GeneGenotypeProteinsEnzyme ActivityResponseLigandsAffectFundingPlasmaProgramsAnticoagulants

Grant awards (87)

Vitamin K gene network: Variant discovery and characterization$314,404

P01 · FY2020 · GM · contact PI

Vitamin K gene network: Variant discovery and characterization$266,280

P01 · FY2019 · GM · contact PI

Vitamin K gene network: Variant discovery and characterization$367,819

P01 · FY2018 · GM · contact PI

F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes$737,011

R24 · FY2017 · GM · contact PI

Vitamin K gene network: Variant discovery and characterization$307,946

P01 · FY2017 · GM · contact PI

F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes$747,826

R24 · FY2016 · GM · contact PI

Vitamin K gene network: Variant discovery and characterization$333,293

P01 · FY2016 · GM · contact PI

New Vistas in Vitamin K Metabolism$286,263

R01 · FY2016 · GM · contact PI

F-CAP: Functionalization of Variants in Clinically Actionable Pharmacogenes$751,729

R24 · FY2015 · GM · contact PI

New Vistas in Vitamin K Metabolism$286,772

R01 · FY2015 · GM · contact PI

Drug Action, Metabolism and Kinetics$469,014

T32 · FY2014 · GM · contact PI

New Vistas in Vitamin K Metabolism$287,245

R01 · FY2014 · GM · contact PI

Drug Action, Metabolism and Kinetics$534,121

T32 · FY2013 · GM · contact PI

New Vistas in Vitamin K Metabolism$287,685

R01 · FY2013 · GM · contact PI

Drug Interactions$1,379,738

P01 · FY2012 · GM · contact PI

Drug Action, Metabolism and Kinetics$604,613

T32 · FY2012 · GM · contact PI

Genotype-Dependent Drug Interactions$448,550

P01 · FY2012 · GM · contact PI

Drug Interactions$283,705

P01 · FY2012 · GM · contact PI

Drug Interactions$1,379,448

P01 · FY2011 · GM · contact PI

Drug Action, Metabolism and Kinetics$597,615

T32 · FY2011 · GM · contact PI

Genotype-Dependent Drug Interactions$361,326

P01 · FY2011 · GM · contact PI

Drug Interactions$278,742

P01 · FY2011 · GM · contact PI

Drug Interactions$1,395,460

P01 · FY2010 · GM · contact PI

Drug Action, Metabolism and Kinetics$590,811

T32 · FY2010 · GM · contact PI

Genotype-Dependent Drug Interactions$443,487

P01 · FY2010 · GM · contact PI

Drug Interactions$440,507

P01 · FY2010 · GM · contact PI

Pharmacogenetics of ADRs: Warfarin Toxicity$392,185

R01 · FY2010 · GM · contact PI

Active Site Models of CYP4 Enzymes$319,541

R01 · FY2010 · GM · contact PI

Drug Interactions$1,386,511

P01 · FY2009 · GM · contact PI

Drug Action, Metabolism and Kinetics$587,500

T32 · FY2009 · GM · contact PI

Genotype-Dependent Drug Interactions$520,237

P01 · FY2009 · GM · contact PI

Pharmacogenetics of ADRs: Warfarin Toxicity$394,808

R01 · FY2009 · GM · contact PI

Drug Interactions$385,202

P01 · FY2009 · GM · contact PI

Active Site Models of CYP4 Enzymes$313,366

R01 · FY2009 · GM · contact PI

Drug Interactions$1,360,630

P01 · FY2008 · GM · contact PI

Genotype-Dependent Drug Interactions$521,729

P01 · FY2008 · GM · contact PI

Drug Action, Metabolism and Kinetics$521,643

T32 · FY2008 · GM · contact PI

Drug Interactions$369,642

P01 · FY2008 · GM · contact PI

Active Site Models of CYP4 Enzymes$304,239

R01 · FY2008 · GM · contact PI

Pharmacogenetics of ADRs: Warfarin Toxicity$142,100

R01 · FY2008 · GM · contact PI

Drug Interactions$1,601,353

P01 · FY2007 · GM · contact PI

Drug Action, Metabolism and Kinetics$537,716

T32 · FY2007 · GM · contact PI

HUMAN CYP2C MODELS$400,093

P01 · FY2007 · GM · contact PI

Pharmacogenetics of ADRs: Warfarin Toxicity$327,421

R01 · FY2007 · GM · contact PI

Active Site Models of CYP4 Enzymes$303,713

R01 · FY2007 · GM · contact PI

CORE - DRUG INTERACTIONS$162,778

P01 · FY2007 · GM · contact PI

Drug Interactions$38,753

P01 · FY2007 · GM · contact PI

Drug Interactions$1,534,432

P01 · FY2006 · GM · contact PI

Drug Action, Metabolism and Kinetics$537,716

T32 · FY2006 · GM · contact PI

Pharmacogenetics of ADRs: Warfarin Toxicity$327,944

R01 · FY2006 · GM · contact PI

HUMAN CYP2C MODELS$267,035

P01 · FY2006 · GM · contact PI

Active Site Models of CYP4 Enzymes$259,442

R01 · FY2006 · GM · contact PI

CORE - DRUG INTERACTIONS$108,682

P01 · FY2006 · GM · contact PI

Drug Interactions$1,526,258

P01 · FY2005 · GM

Drug Action, Metabolism and Kinetics$537,716

T32 · FY2005 · GM

Pharmacogenetics of ADRs: Warfarin Toxicity$347,173

R01 · FY2005 · GM

Active Site Models of CYP4 Enzymes$265,816

R01 · FY2005 · GM

HUMAN CYP2C MODELS$259,257

P01 · FY2005 · GM

CORE - DRUG INTERACTIONS$105,554

P01 · FY2005 · GM

Drug Interactions$1,482,179

P01 · FY2004 · GM

Drug Action, Metabolism and Kinetics$573,564

T32 · FY2004 · GM

Pharmacogenetics of ADRs: Warfarin Toxicity$361,135

R01 · FY2004 · GM

HUMAN FMO'S DETERMINANTS OF SUBSTRATE SPECIFICITY$266,000

R01 · FY2004 · GM

Active Site Models of CYP4 Enzymes$265,942

R01 · FY2004 · GM

HUMAN CYP2C MODELS$251,706

P01 · FY2004 · GM

CORE - DRUG INTERACTIONS$102,517

P01 · FY2004 · GM

Drug Interactions$1,622,438

P01 · FY2003 · GM

DRUG ACTION, METABOLISM AND KINETICS$519,374

T32 · FY2003 · GM

Active Site Models of CYP4 Enzymes$266,064

R01 · FY2003 · GM

HUMAN FMO'S DETERMINANTS OF SUBSTRATE SPECIFICITY$266,000

R01 · FY2003 · GM

HUMAN CYP2C MODELS$244,375

P01 · FY2003 · GM

CORE - DRUG INTERACTIONS$184,568

P01 · FY2003 · GM

DRUG INTERACTIONS$1,189,060

P01 · FY2002 · GM

DRUG ACTION, METABOLISM AND KINETICS$486,106

T32 · FY2002 · GM

HUMAN FMO'S DETERMINANTS OF SUBSTRATE SPECIFICITY$266,000

R01 · FY2002 · GM

ACTIVE SITE MODELS OF MAMMALIAN CYP4 ISOFORMS$198,389

R01 · FY2002 · GM

CORE--BIOTRANSFORMATION AND DISPOSITION$73,467

P30 · FY2002 · ES

HUMAN FMO'S DETERMINANTS OF SUBSTRATE SPECIFICITY$40,000

R01 · FY2002 · GM

DRUG ACTION, METABOLISM AND KINETICS$452,030

T32 · FY2001 · GM

HUMAN FMO'S DETERMINANTS OF SUBSTRATE SPECIFICITY$263,725

R01 · FY2001 · GM

ACTIVE SITE MODELS OF MAMMALIAN CYP4 ISOFORMS$192,698

R01 · FY2001 · GM

CORE--BIOTRANSFORMATION AND DISPOSITION$117,868

P30 · FY2001 · ES

CORE--BIOTRANSFORMATION AND DISPOSITION$117,868

P30 · FY2001 · ES

CORE--BIOTRANSFORMATION AND DISPOSITION$73,467

P30 · FY2001 · ES

ACTIVE SITE MODELS OF MAMMALIAN CYP4 ISOFORMS$187,173

R01 · FY2000 · GM

CORE--BIOTRANSFORMATION AND DISPOSITION$117,868

P30 · FY2000 · ES

CORE--BIOTRANSFORMATION AND DISPOSITION$117,868

P30 · FY2000 · ES